Related Experiment Video
Updated: Feb 2, 2026

Acute and Chronic Tactile Sensory Testing after Spinal Cord Injury in Rats
Published on: April 4, 2012
Inhibitory Effects of Mas-Related Gene C Receptor on Chronic Morphine-Induced Spinal Glial Activation in Rats
Yunshan Zhang1, Mei Wang1, Qiuhua Lu1
1Provincial Key Laboratory of Developmental Biology and Neuroscience, Fujian Normal University, Fuzhou, Fujian, China.
Abstract:
Glial activation plays a pivotal role in morphine tolerance. This study investigated effects of Mas-related gene (Mrg) C receptor on morphine-induced activation of microglia and astrocytes in the spinal cord and its underlying mechanisms. Intrathecal administration of morphine (20 μg, daily) for 6 days induced a great decline in morphine antinociception and increased expression of glial fibrillary acidic protein and OX-42 in the spinal dorsal horn. These changes were greatly attenuated by the intermittent coinjection of bovine adrenal medulla 8-22 (BAM8-22, 1 nmol), a specific agonist of MrgC receptor. These modulatory effects were accompanied by the reduction of P2X4 and interleukin-1β expressions in the spinal dorsal horn. Chronic morphine increased the expression of fractalkine in medium- and small-sized neurons of dorsal root ganglia (DRG). Treatment with BAM8-22 inhibited these changes as well as an increase in Toll-like receptor 4 (TLR4) protein in DRG. Chronic treatment of DRG explant cultures with morphine (3.3 μM, 5 days) increased the levels of fractalkine mRNA. Application of BAM8-22 (10 nM) for 60 minutes completely blocked the increase of fractalkine mRNA induced by morphine. Our findings indicate that the inhibition of morphine tolerance by MrgC receptor was associated with the modulation of astrocytes and microglia in the spinal dorsal horn and fractalkine and TLR4 expressions in DRG. As MrgC receptor is exclusively located in DRG, intermittent combination of MrgC receptor agonist could be a promising adjunct with limited side effects for chronic use of opiates.
Insights
Activating Mas-related gene C receptors with BAM8-22 reduces morphine tolerance by modulating spinal glial cells and dorsal root ganglia pathways. This suggests MrgC receptor agonists may aid chronic opiate use with fewer side effects.
Area of Science:
- Neuroscience
- Pharmacology
- Pain Research
Background:
- Glial activation is crucial in developing morphine tolerance.
- Mas-related gene (Mrg) C receptors are implicated in pain modulation.
Purpose of the Study:
- To investigate the effect of MrgC receptor activation on morphine-induced glial activation in the spinal cord.
- To explore the underlying mechanisms of MrgC receptor-mediated modulation of morphine tolerance.
Main Methods:
- Intrathecal morphine administration in rats to induce tolerance.
- Treatment with BAM8-22, a specific MrgC receptor agonist.
- Analysis of glial markers (GFAP, OX-42), P2X4, IL-1β, fractalkine, and TLR4 expression.
- DRG explant cultures to study fractalkine mRNA levels.
Main Results:
- Morphine-induced antinociceptive decline and glial activation were attenuated by BAM8-22.
- BAM8-22 reduced P2X4 and IL-1β expression in the spinal cord.
- Morphine-induced increases in fractalkine and TLR4 in DRG were inhibited by BAM8-22.
- BAM8-22 blocked morphine-induced increases in fractalkine mRNA in DRG explants.
Conclusions:
- MrgC receptor activation inhibits morphine tolerance by modulating spinal glial cells and DRG pathways.
- The findings suggest MrgC receptor agonists as potential adjuncts for chronic opiate therapy.
- Targeting MrgC receptors may offer a strategy for managing opioid-induced side effects.
Related Concept Videos
Excitatory and Inhibitory Effects of Neurotransmitters
Internal Receptors
Opioid Analgesics: Morphine and Other Natural Cogeners
Glial Cells
Receptor-mediated Endocytosis
Co-activators and Co-repressors

